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ABSTRACT 
Background: Haemophilia A is a congenital bleeding disorder due to deficiency of 
clotting Factor VIII (FVIII) and is treated by replacement therapy using FVIII 
clotting factor concentrates. The most serious complication is the development of 
a neutralizing inhibitor to exogenous FVIII requiring treatment with a bypassing 
agent. Routine measurement of inhibitors is important in the diagnosis, therapeutic 
monitoring and surveillance of inhibitor patients. The testing of inhibitor is 
historically performed with the Bethesda assay (BA) which lacks specificity and 
reliability when it comes to the low-titre inhibitor ranges. The Nijmegen 
modification of the Bethesda assay (NA) was developed and proven superior to 
the BA. With routine inhibitor monitoring, the phenomenon of transient low-titre 
inhibitor is noted, they disappear spontaneously and patients do not require a 
change in treatment.  The aim of this study was to validate NA in the routine 
National Health Laboratory Service (NHLS) haematology laboratory at Charlotte 
Maxeke Johannesburg Academic Hospital (CMJAH) and the haemophilia clinic at 
CMJAH using different buffered reagents and to determine the significance of the 
transient inhibitors using a cohort of inhibitor patients attending our haemophilia 
clinic. Methods: A total of 100 samples from both low- and high-titre inhibitor 
patients were collected in our centre over the period of 2007 to 2013 when 
patients had their routine clinic visits. Validation of NA, including the set-up and 
optimization of the NA, was done as described by Verbruggen (2014). The normal 
pooled plasma (NPP) and Dade® Citrol 1® Coagulation Control Level 1 (Citrol 1) 
were buffered with imidazole. Using either the NPP or Citrol 1, the NA was 
performed on 3 control samples (provided by External quality Control of diagnostic 
Assays and Tests (ECAT) foundation) and on all 100 patient samples. Precision 
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analysis was performed on a control sample to determine standard deviation (SD) 
and coefficient of variation (CV). Accuracy analysis was performed on patient- 
samples against BA and results expressed as bias and 95% confidence interval. 
Linearity analysis was performed in the low-titre range between 0 to 5 BU/mL. 
Clinical data of the corresponding patients were collected and analyzed to 
determine the clinical significance of transient inhibitor. Results: Of the 100 
patient-samples,100 were analyzed with NPP and 43 with Citrol 1. In the NA using 
NPP, the control plasma CV was 8.44% (95%CI of 0.77 ± 0.05) with a SD of 0.06. 
In the NA using Citrol 1, the control plasma CV was 10% (95%CI of 0.93 ± 0.02) 
and SD was 0.09. In the Bland-Altman plot of NA against BA using the NPP, the 
bias was 0.49 (95%CI of -8.1 to 9.1). The bias between NA and BA using Citrol 1 
was 0.8 (95%CI of -6.8 to 8.5). The correlation coefficient of NA vs BA using the 
NPP was 0.93 and that of the NA vs BA analysis using the Citrol 1 was 0.76. All 
control plasma analyses using NPP buffered by 4M imidazole solution were within 
reference values whilst only 2 of 3 values were within the assigned values using 
Citrol 1. Only 3 of 20 high-titre inhibitor patients have a history of transient 
inhibitor. The inhibitors in the residual 44 patients with low titre inhibitors were of 
transient nature and these patients have not developed clinically significant 
inhibitors to date. Conclusion: In this analysis of patient and control samples with 
inhibitors, the analytical performance of the NA was comparable to BA. The 
performance of the Nijmegen assay with buffered pool plasma was better than that 
of the same assay using buffered Citrol 1. In this study, the presence of transient 
inhibitor did not seem to predict future inhibitor development in our haemophilia 
cohort.   
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1 INTRODUCTION 
1.1 Overview of haemophilia 
Haemophilia is a congenital bleeding disorder due to deficiency of a coagulation 
clotting factor. Deficiency of factor VIII (FVIII) is called Haemophilia A and occurs 
in 1 in 5000 live male births. Factor IX (FIX) deficiency is called Haemophilia B and 
occurs in 1 in 25 000 live male births1. Treatment of haemophilia is by replacement 
of the missing protein, which may be plasma derived or recombinant factor. 
Haemophilia patients are categorized into three groups depending on their 
baseline factor levels: mild (>5% - <40%) , moderate (1% - 5%) and severe 
(<1%)2. 
 
1.1.1 Genetics of haemophilia 
Haemophilia is a X-linked recessive inherited disorder (see Figure 1.1) where the 
mutated gene occurs on the X chromosome causing the expression of phenotype 
in males (only one X chromosome) and homozygous females. Mutation in the F8 
gene leads to abnormal FVIII clotting factor production resulting in Haemophilia A 
and F9 gene mutations similarly result in Haemophilia B3. 
 
The F8 gene is located cytogenetically on the long arm of the X chromosome at 
band Xq28. Two additional genes F8A and F8B are nested within intron 22 which 
is the largest intron within the F8 gene. The most common mutation in 
Haemophilia A involves intron 22 inversion due to homologous recombination4. F9 
gene is also located on the long arm of the X chromosome but on band Xq27. The 
most common mutation in Haemophilia B result from single-base substitution5 . 
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Acquired haemophilia is however not an inherited disorder but relates to the 
production of autoantibodies targeting specific coagulation factors such as FVIII 
and FIX. Causes include drugs, pregnancy, postpartum state, underlying 
autoimmune diseases and dermatological conditions or it can be idiopathic. The 
management of acquired haemophilia involves bypassing agents for acute bleeds 
and inhibitor eradication long term6. 
 
1.1.2 Clinical presentation  
The deficiency of clotting factor (FVIII or FIX) leads to bleeding due to impaired 
haemostasis. Clinical presentation depends on the severity of the disease. In mild 
haemophilia, patients are generally asymptomatic and bleeds often occur after 
trauma or surgery (delayed bleeding may be experienced after dental procedure). 
Individuals with mild haemophilia may present later in life if they have not had a 
haemostatic challenge7. In moderate haemophilia, individuals usually bleed after 
minor injury or invasive procedure. In the presence of a target joint, bleeding may 
be more frequent and spontaneous. In severe haemophilia, bleeds are usually 
disproportionate to the degree of trauma, spontaneously bleeding into joints is 
common. These individuals usually present early in life (within first year of life) with 
haemarthrosis, spontaneous haematoma in muscles or after invasive procedures 
(such as venepunctures and circumcision)8, 9. Urogenital bleeds (kidney or 
bladder) are frequent in severe haemophilia and if managed appropriately, does 
not result in loss of renal function10. Although it is rare, spontaneous or post-
traumatic intracranial haemorrhage is one of the most serious, life-threatening 
bleeding events in severe haemophilia which can occur at any age11-13. 
Occasionally, intracranial haemorrhage can occur at birth14.  
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1.1.3 Diagnosis  
The diagnosis of haemophilia is made by a combination of patient’s bleeding 
history, family history and laboratory testing.  
 
Pertinent bleeding history in haemophilia includes bleeding symptoms, severity of 
bleeding and response to haemostatic challenges15. Family history may be 
negative in up to one third of haemophilia patients due to spontaneous mutation in 
F8 or F9 gene16.   
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Figure 1.1. Inheritance pattern of Haemophilia. 
A. Carrier mother with unaffected father and possible offspring. B. Affected father with unaffected mother and possible offspring. C. 
Affected father with carrier mother and possible offspring. Symbols: , unaffected male; , unaffected female; , carrier female; , 
affected male. Abbreviations:  XY, father; XXH, carrier mother; XHY, father with haemophilia; XX, mother.
A. X-linked recessive, carrier mother 
XY XXH 
Unaffected 
son 
B. X-linked recessive, affected father 
XX XHY 
Unaffected 
daughter 
Carrier 
daughter 
Affected 
son 
Unaffected 
son 
Carrier 
daughter 
Carrier 
daughter 
Unaffected 
son 
C. X-linked recessive, affected 
father and carrier mother 
XXH XHY 
Affected 
son 
Affected 
daughter 
Carrier 
daughter 
Unaffected 
son 
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An approach to laboratory diagnosis includes a tiered approach starting with 
screening tests moving to definitive tests: 
 Screening tests using:   
 prothrombin time (PT) for extrinsic coagulation pathway;  
 activated partial thromboplastin time (aPTT) for intrinsic coagulation 
pathway;  
 bleeding time;  
 platelet count and functions for platelet quantity and quality testing15. 
 An isolated prolonged aPTT which corrects on mixing studies (by mixing 
50% test plasma with 50% normal pooled plasma) indicate a factor 
deficiency. Individual factors such as FVIII and FIX should then be assayed. 
A normal aPTT does not exclude the diagnosis of mild haemophilia, 
therefore definitive testing such as factor activity should be performed 
regardless of aPTT results if clinically indicated. In the presence of FVIII 
deficiency, von Willebrand disease should be excluded15. 
 If screening tests yield an isolated prolonged aPTT which does not correct, 
the presence of an inhibitor should be suspected. Inhibitor testing by 
Bethesda assay (BA) or Nijmegen modification of the Bethesda assay (NA) 
should be performed15. 
 Genetic testing for specific mutations is indicated in most haemophilia 
patients once the diagnosis is made. It aids to predict the risk of inhibitor 
formation and identification of carrier status in female family members17.  
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1.1.4 Treatment  
The principle to achieve haemostasis in haemophilia is to replace the missing 
clotting factor. Clotting factor concentrates (CFC) are the treatment of choice (i.e. 
FVIII concentrates for haemophilia A and FIX concentrates for haemophilia B). 
The CFC are available in plasma-derived and recombinant formulations. Other 
sources for clotting factors include activated prothrombin complex concentrate 
(aPCC), cryoprecipitate and fresh frozen plasma (FFP), but these are generally 
utilized when CFC are not available. In addition to CFC, other pharmacological 
agents, which include antifibrinolytics and desmopressin, showed variable 
success15.  
 
1.2 Complications of haemophilia treatment 
Clotting factor concentrate and many plasma-derived sources of clotting factor 
may give rise to transfusion-transmitted viral infections such as human 
immunodeficiency virus (HIV), Hepatitis B virus (HBV) and hepatitis C virus (HCV). 
Bacterial infections are possible because venous access is necessary15, 18.  
 
Intra-articular joint and intramuscular bleeds are common and frequent in severe 
haemophilia. Inadequate and/or delayed CFC treatment and recurrent joint bleeds 
lead to progressive deterioration of joints and permanent joint deformities and 
dysfunction18. 
 
The most serious and challenging complication of CFC replacement therapy in 
haemophilia is the development of antibodies (inhibitors) against replacement 
coagulation protein19 rendering the substitution factor therapy ineffective. A recent 
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systematic review demonstrated that the overall prevalence of inhibitors in the 
haemophilia population was 5% - 7%20. In the case of congenital haemophilia 
these are alloantibodies characterized by an anamnestic response and in acquired 
haemophilia these are autoantibodies21, 22.  
 
In up to 50% of haemophilia B patients with inhibitors, severe allergic reaction may 
occur to FIX concentrates administration15. 
 
1.3 Inhibitors 
Inhibitors are polyclonal high-affinity immunoglobulin G (IgG) antibodies against 
FVIII23, 24 or FIX25. Inhibitors develop in ± 25-30% of severe haemophilia A and 3-
5% in haemophilia B18.  
 
1.3.1 Types of inhibitor 
There are two types of inhibitors: Type 1 and Type 2. Type 1 inhibitors are 
alloantibodies that neutralize factor VIII in direct proportion to their concentration21 
(see Figure 1.2). It is subdivided further into 2 types: high responding and low 
responding. High responding inhibitors are defined as those with high antibody 
titre of > 5 BU/mL which appear rapidly after factor exposure. Low responding 
inhibitors show little to no response upon exposure to factor and titres remain less 
than 5 BU/mL2, 26. Type 2 inhibitors are usually autoantibodies that neutralize 
factor VIII rapidly initially, followed by a slow phase of inactivation where residual 
factor VIII can be measured 21 (see Figure 1.2). The in vivo autoantibody potency 
is poorly correlated with the residual FVIII measured in vitro22. The differences 
between auto- and allo-antibodies are summarized in Table 1.1. 
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Figure 1.2. Kinetics of type 1 and type 2 inhibitors against Factor VIII. 
Type 1 inhibitor shows a linear relationship between time incubated and 
neutralisation of Factor VIII activity with eventual complete neutralisation of Factor 
VIII. Type 2 inhibitor shows an initial neutralisation phase then a plateau with some 
residual Factor VIII (which can be detected in vitro). Adapted from Ma and 
Carrizosa21 
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Table 1.1. Differences between allo- and autoantibodies. Adapted from 
Green22 
  Alloantibody Autoantibody 
 
Patients type Haemophilia Non-haemophilia 
 
Origin Therapy-related Spontaneous 
 
Bleeding site Predominantly Joints Predominantly skin & soft 
tissue 
 
Effect on 
haemostasis 
Disrupt FVIII-FIX complex 
formation 
Alter binding of VWF and 
phospholipids to FVIII 
 
Kinetics Type 1 Type 2 
 
Acute 
Management 
<5 BU/mL: FVIII 
concentrates;  
>5 BU/mL: Bypassing 
agents 
 
Bypassing agents 
Long Term 
Management 
Immune tolerance 
induction 
 
Inhibitor Eradication with 
immunomodulatory 
therapies 
 
Abbreviations: FVIII, factor VIII; FIX, factor IX, VWF, von Willebrand factor; BU/mL, 
Bethesda unit per millilitre. 
 
 
1.3.1.1 Transient inhibitors 
“Transient” inhibitors are low-titre antibodies that appear and disappear 
spontaneously over a non-defined amount of time without any specific 
intervention23, 27. These transient inhibitors represent 20-55% of all inhibitors 
reported in recombinant FVIII studies28, 29. Some literature defined transient 
inhibitors as inhibitors that spontaneously disappear within 6 months28. However,  
a recent prospective study suggests some of these low-titre inhibitors only 
eventually disappear over 3-6 years30.  The presence of transient inhibitors in 
haemophilia patients suggests that possible natural tolerance occurred to the 
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given exogenous factor23, 27. There is not much literature available regarding the 
long term relevance of these inhibitors. It is also not clear if the transient inhibitors 
can predict future inhibitor development. 
 
 
1.3.2 Definition of clinically relevant inhibitor development 
Clinically relevant inhibitor development was defined by at least two positive 
inhibitor titre measurements with reduced in vivo factor recovery31. A positive 
inhibitor titre is defined as ≥0.6 BU/mL. The predicted factor recovery 30 minutes 
after FVIII infusion is based on the assumption that 1IU of FVIII per kilogram of 
body weight will raise the FVIII level to 2%. A reduction of factor recovery is 
defined as less than 66% of the expected rise in factor level32. 
 
1.3.3 Risk factors 
Risk factors for inhibitor development in congenital haemophilia are multifactorial 
and include both genetic and acquired causes (see Table 1.2). Research 
conducted in PUP (previously untreated patients) for the development of inhibitors 
are important because these patients are FVIII naïve and therefore give a better 
indication of immunogenicity of CFC. In PUP research, both patient- and 
treatment-related factors contributing to the patients’ immune response to the 
exogenous FVIII are considered. In  PTP (previously treated patients), the 
development of inhibitors is considered less likely as they are already tolerized to 
replacement CFC33, 34.  
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Table 1.2. Risk of inhibitor development in PUPs and PTPs33, 34. 
Previously untreated patients 
 
Previously treated patients 
Age of first exposure Product-related immunogenicity 
(including neo-epitopes in novel 
products) 
 
Genetics 
- Mutation type 
- Polymorphisms 
- Immune regulatory genes 
 
 
Race 
 
 
Family history 
 
 
Environmental: 
- Intense FVIII exposure 
- Surgery 
- Early introduction to prophylaxis 
 
 
Abbreviations: PUP, previously untreated patients; PTP, previously treated 
patients. 
 
1.3.3.1 Patient-related factors 
1.3.3.1.1 Age 
Inhibitor development is highest in children ≤ 5 years of age with a cumulative risk 
of 16%. A second peak is seen at an older age of ≥ 60 years with a cumulative 
risk of 36% by 75 years35, 36. The reason for inhibitor development at older age 
may be due to loss of tolerance and exposure to danger signals (such as surgery 
and intensive therapy) and immune dysregulation associated with advanced age35, 
37.  
 
1.3.3.1.2 Severity of disease 
Haemophilia patients with severe disease have a significant higher incidence of 
inhibitor development than patients with mild to moderate disease. The prevalence 
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for the severe haemophilia population to develop inhibitors is 12% - 13%20, 35 and 
incidence of up to 30%20, 38 in severe haemophilia A and 2% - 5% in severe 
haemophilia B39. Incidence of inhibitor development as a function of severity of 
haemophilia is demonstrated in Table 1.3. 
 
Table 1.3. Incidence of inhibitor development with severity of haemophilia 
A20, 39. 
Haemophilia Severity Incidence of inhibitor development 
Mild/moderate haemophilia 2 – 8% 
Severe haemophilia Up to 30% 
 
 
1.3.3.1.3 Genetics 
The type of FVIII mutation is strongly correlated with the risk for inhibitor 
development. High risk mutations include large deletion, null mutation, nonsense 
mutation and introns 22 inversion (see Table 1.4). Large multidomain deletions are 
particularly associated with increased prevalence of high-titre inhibitor 
development. In addition, immune response gene polymorphism (e.g. involvement 
of interleukin 10 and tumor necrosis factor alpha) shows a contribution to inhibitor 
development40, 41. 
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Table 1.4. FVIII mutations and inhibitor prevalence of Haemophilia A41. 
Mutation 
 
Inhibitor prevalence (%) 
Large deletions 
 Multidomain 
 Single domain 
 
41 
88 
25 
Non sense mutations 
 Light chain 
 Heavy chain 
 
31 
40 
17 
Intron- 22 inversion 
 
21 
Small deletions 
 
16 
Missense 
 C1/C2 domain 
 Non C1/C2 domain 
 
5 
10 
3 
Splice site 
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In addition to the F8 gene mutations, a positive family history with inhibitor 
development as well as ethnicity (in particularly black and subgroup of Hispanic, 
Asian and Indian families) were associated with a higher incidence of inhibitor 
development42-45.  
 
A recent study conducted in South Africa showed that black patients with 
haemophilia had a higher frequency of the intron 22 mutation and inhibitor 
development than white patients in South Africa. The findings support a significant 
association between inhibitor development, ethnicity and F8 gene mutation type46. 
 
1.3.3.1.4 HIV status 
Infection with the HIV, in the majority of haemophilia patients, is a consequence of 
transfusion transmission which predates the general screening methods used to 
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date. The impact of HIV on haemophilia has unprecedented high morbidity, 
however, some patients are long term non-progressors. There is no documented 
association between the HIV and incidence for inhibitor development35, 36. 
 
1.3.3.2 Treatment-related factors 
1.3.3.2.1 Prophylaxis 
Factor replacement therapy can be given by two different strategies, namely: on-
demand and prophylactic therapy. On-demand treatment is defined as factor 
replacement therapy given when bleeding has already occurred. Prophylactic 
therapy is factor replacement therapy given to prevent bleeding. On-demand 
treatment is associated with higher risk of developing inhibitor whilst prophylactic 
treatment seems to have a protective effective against inhibitor development38, 47. 
Prophylaxis, particularly in children appears to have a tolerizing effect with 
resultant low incident of inhibitors  
 
1.3.3.2.2 Age at first exposure to treatment 
Younger age (especially <1 year of age) of the first exposure to replacement 
therapy is strongly associated with higher risk of inhibitor development45, 48, 49. This 
is in part because the immune system is not yet mature to differentiate self from 
non-self antigens. 
 
1.3.3.2.3 Intensity of treatment 
Inhibitor development in mild to moderate haemophilia patients are usually rare 
(risk of ~5%)24. However, intensive factor therapy (in particular, via continuous 
infusion) is associated with increased incidence of inhibitor formation in children 
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with mild or moderate disease50. Intensive factor therapy is defined as high dose 
replacement therapy with CFC over a short period of time. 
 
In adult patients, intensive treatment is commonly associated with surgery and the 
post-operative period. The intensive CFC treatment contributes to inhibitor 
formation in the non-severe adult haemophilia population51.  
 
Trauma, ischemia and tissue damage can cause inflammatory responses. These 
cell-damage associated molecule patterns (DAMPs) present danger signals that 
can stimulate inflammatory responses of the innate immune system that ultimately, 
but indirectly, lead to upregulation of antibody responses52. It was proposed that 
avoiding these immunological danger signals decreased the development of 
inhibitors53. 
 
1.3.3.2.4 Exposure days 
Most inhibitors tend to develop within 10-15 exposure days (but generally within 50 
exposure days) to CFC in the severe haemophilia population. After 50-75 
exposure days, the cumulative rate for inhibitor development reaches a plateau54, 
55 and the formation of inhibitor after 150 exposure days is very rare41, 56. 
  
1.3.3.2.5 Types of replacement products 
Multiple prospective observational studies (RODIN, EUHASS, GTH PUP study 
and PEDNET) and randomized controlled trials (SIPPET) have been conducted to 
study the relationship between inhibitor development and the type of replacement 
products (recombinant factor and plasma-derived factor products). See Table 1.5 
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for results. The SIPPET study showed rFVIII is associated with a 1.87-fold higher 
incidence for inhibitor development than pdFVIII products. In addition, switching 
between products does not make a difference to the development of inhibitors56-58. 
 
Table 1.5. Prospective observational studies (RODIN, EUHASS, GTH PUP 
and SIPPET) results for inhibitor development29, 58-60. 
Study pdFVIII [n/N, cumulative 
incidence (%)] 
 
rFVIII [n/N, cumulative 
incidence (%)] 
EUHASS 2015 11/51 (21.6%) 97/366 (26.5%) 
 
RODIN 2013 29/88 (33.1%) 148/486 (32.3%) 
 
GTH  2003 11/49 (22%) 20/63 (32%) 
 
SIPPET 2015 29/125 (26.7%) 47/126 (44.5%) 
 
Abbreviations: pdFVIII, plasma derived factor VIII; rFVIII, recombinant factor VIII; 
n, number of positive patients; N, total number of patients in the study. 
 
There are two types of recombinant CFC, namely full-length recombinant factor 
VIII (FLRFVIII) and B-domain-deleted/-truncated recombinant factor VIII 
(BDDRFVIII). The BDDRFVIII is a recombinant factor VIII product made with the 
B-domain (which is 908 amino-acid) removed except for a 14 amino-acid linker 
sequence (which is known as the SQ-peptide). Some authors suggest the function 
of the large and highly glycosylated B-domain is important for the intra-cellular 
processing and secretion of FVIII but unnecessary for coagulant activity61, 62. Both 
efficacy and immunogenicity (i.e. inhibitor development) of BDDRFVIII have been 
shown to be similar to that of FLRVIII in a few prospective studies and meta-
analysis33, 63, 64. 
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1.3.3.3 Risk factors for acquired inhibitor development 
Occasionally autoantibodies against factor VIII develop in non-haemophilia 
patients (acquired factor VIII inhibitors). Some of the reasons for development of 
autoantibodies include the following: 
 HIV infection: very rare, only a few cases reported internationally and 
appears to be independent of treatment or CD4 count/degree of 
immunodeficiency65-67,  
 pregnancy and postpartum state (8%) usually at term or early postpartum 
period, alteration of immune state of third trimester or parturition may be 
contributing to the development of inhibitors68-70,  
 underlying autoimmune disorder (17-18%) such as rheumatoid arthritis 
(8%), systemic lupus erythematosus (6%) and Sjögren’s syndrome68,  
 malignancy (12%) including both solid tumours (squamous cell carcinoma 
of lung, prostate, pancreas, colon and hypernephroma) and haematological 
malignancy (such as plasma cell dyscrasias and lymphoproliferative 
disorders) in both cancer and precancerous state68, 69,  
 drugs (5-10%) including interferon for the treatment of HCV, penicillin, sulfa 
drugs, phenytoin and chloramphenicol6, 67, 69, 
 dermatological conditions (5%) such as psoriasis, pemphigus vulgaris, 
erythema multiforme and non-specific dermatosis which may be related to 
drug reaction or underlying autoimmune state68, 
 idiopathic which comprises approximately 50% of the cases69, 70.  
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1.3.4 Clinical significance 
1.3.4.1 Morbidity and quality of life 
Patient with inhibitors experience more difficulty in achieving haemostasis which 
leads to more frequent bleeding phenotype. Acute and chronic synovitis also 
contribute to the increased bleeding episodes. Musculoskeletal bleeds and 
orthopaedic procedures in inhibitor patients are significantly increased in 
comparison to patients without inhibitors39. Hospitalization, outpatient routine, 
emergency room (ER) visits and subsequently absence from work/school are 
noted to be higher in inhibitor patients. Significant amount of inhibitor patients 
reported chronic joint pain and reduced mobility which require walking aids or 
wheelchair usage. These complications resulted in general decreased QOL39, 71, 72.  
 
1.3.4.2 Therapeutic management and cost of inhibitor patients 
Management of inhibitor patients generally requires a highly trained team as well 
as resources that are not readily available. Overall, the therapeutic options for 
haemostasis, as well as inhibitor eradication/immune tolerance induction, are not 
optimal with unpredictable effectiveness24.  
 
1.3.4.2.1 Management of haemorrhagic episodes 
Treatment of acute bleeds should be provided as soon as possible. For patients 
with low-responding inhibitors, the treatment usually involved replacement therapy 
with CFC (at normal or higher dosage). Patient with high-titre inhibitors will require 
bypassing agents (such as aPCC/factor eight inhibitor bypassing activity (FEIBA®) 
or rFVIIa/NovoSeven® or both, see Table 1.6). Patients may respond better to one 
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than the other.  Owing to the unpredictable response, general recommendation is 
not possible24, 41. 
 
Table 1.6. The advantages and disadvantages of aPCC (FEIBA®) and rFVIIa 
(NovoSeven®). Adapted from Kulkarni et al.73 
Type of product Advantages Disadvantages 
 
rFVIIa 
(NovoSeven®) 
No known risk of viral 
transmission 
Devoid of human serum or 
proteins 
Absent anamnestic 
response 
 
Short half-life 
Risk of thrombosis 
aPCC (FEIBA®) Long half-life 
Virally inactivated 
Less expensive than 
rFVIIa 
Plasma-derived product 
Risk of thrombosis 
Possible anamnestic 
response 
Allergic reaction 
Abbreviation: rFVIIa, activated recombinant factor 7; aPCC, activated prothrombin 
complex concentrate. 
 
1.3.4.2.2 Long term management 
Long term management of high-titre patients are generally aimed at immune 
tolerance induction (ITI) in patients (mostly children) with alloantibodies and 
inhibitor eradication in adults with autoantibodies6, 24.  
 
Eradication of autoantibodies involves the use of prednisone (1 mg/kg/day) alone 
or in combination with oral cyclophosphamide (1-2 mg/kg/day) as first line 
treatment74, 75. Rituximab is an anti-CD20 monoclonal antibody used alone or in 
combination with other immunosuppressant as first- or second-line therapy for 
autoantibodies eradication. In addition, calcineurin inhibitors and mycophenolate 
mofetil are used as alternatives to rituximab in patients who did not respond to the 
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first line treatment74. There is no recommendation for optimal immunosuppressive 
regimen and duration of treatment for autoantibodies eradication76. 
 
Immune tolerance induction can be high (FVIII, 200 U kg-1 day-1) or low (50 U kg-1 
thrice weekly) dose regimen and involves repeated doses of FVIII product and 
bypassing agent infusion with or without immunomodulation until the 
disappearance of alloantibodies24, 41. Dosage of the ITI, time between inhibitor 
diagnosis and initiation of ITI, maximum titre and age at treatment all affect the 
outcome. It was noted that high dose ITI has less bleeding complication than low-
dose ITI77. If patients do not achieve tolerance by 2 years (i.e. inhibitor persisted), 
it is deemed as failure of ITI24, 78.  
 
Short and long term management of inhibitor patients remain extremely expensive 
and estimated in the region of 18000 Euros per month79 (see Table 1.7).  
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Table 1.7. Cost of care in haemophilia patients with inhibitor. Adapted from Di 
Minno et al.79 
Average annual concentrate costs 1.5- to 3-fold higher in inhibitor patients than 
in non-inhibitor patients 
 
The highly expensive care provides a satisfactory quality of life in haemophilia 
with inhibitors 
 
Monthly cost/patient ~18 000 €; ~50% of patients require <5000 € per month, 
only 2% needing >100 000 € 
 
Costs of ITI: ~8-fold higher FVIII consumption and costs in patients with 
unfavourable prognosis 
 
Mean annual costs of on-demand treatment in an inhibitor patient are 3-fold 
higher than in non-inhibitor patients 
 
Mean ITI costs are 3-fold higher in high-responder than in low-responder 
children. Higher differences in adults 
 
Abbreviation: ITI, Immune tolerance induction. 
 
1.4. Measurement of inhibitors 
1.4.1 Bethesda assay (BA) and its limitations 
The presence of inhibitor is most commonly diagnosed using the Bethesda Assay 
(BA) which was developed in 197519, 80. The BA involves serial dilution of patient’s 
plasma (containing the inhibitor) with normal pooled plasma (source of FVIII). The 
mixtures are then incubated at 37˚C for 2 hours (allowing FVIII from NPP to be 
inactivated by inhibitor from test plasma). Residual clotting factor activity in the 
mixture is determined by standard one stage clotting assay.  
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Figure 1.3. Flow diagram of Bethesda Assay81. 
 
Clinically relevant inhibitor development was defined by two positive-titre 
measurements (>0.6 BU/mL) with reduced factor recovery of <66% of expected 
rise. Bethesda Assay is sensitive, however lacks specificity and reliability in the 
low titre inhibitor range (defined as 0.4 – 5 BU/mL, but in particularly 0.4 – 1.0 
BU/mL) owing to the following: 
 pH of the test mixture increased to 8.4 – 8.6 during the 2-hour incubation in 
37°C waterbath denaturing the FVIII; 
 protein denaturation during the incubation period further decreasing FVIII 
activity.  
 it was also noted that during serial dilution, the inhibitor activity increased 
proportionally despite no clinical evidence of an inhibitor. 
Patient plasma
Normal pool 
plasma
Imidazole 
(Owren-Koller) 
buffer
Control mixture
1:1
Test mixture
1:1
Perform factor assay
Incubate at 37˚C for 2 hours
Calculate inhibitor units
23 
 
Overall, the non-specific low-titre inhibitor measured is due to the presence of 
experimental artefact82, 83. 
 
The Nijmegen modification (NA) of the Bethesda assay was therefore developed 
to improve the specificity and reliability for low titre inhibitor testing in 199582. 
 
1.4.2 Nijmegen modification of the Bethesda assay (NA) 
The Nijmegen modification proposed two changes to the current Bethesda assay: 
(a) normal pooled plasma is buffered to pH7.4 with 0.1M imidazole buffer and (b) 
FVIII-deficient inhibitor-free plasma is used in the place of imidazole buffer (in our 
centre - Owren-Koller buffer)82. This is subsequently followed by serial dilution, 
incubation, residual clotting factor activity measurement and calculation of inhibitor 
level as per original BA.  
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Figure 1.4. Flow diagram of Nijmegen Assay81. 
 
These modifications improve the intrinsic buffering effect after serial dilution 
thereby improving the specificity and reliability of the test for low-titre inhibitor 
without altering the sensitivity. With the regards to high-titre inhibitors, NA offers 
the similar specificity to BA but the quantification is erroneous owing to the 
complex non-linear kinetics between FVIII and its inhibitors82, 84.  
 
The inter-laboratory CV for NA is approximately 50% and had remained high over 
the years due to the differences in reagents used, normal pooled plasma as well 
as buffering methods. Centralized testing was recommended85, 86.  
 
Additional recommendation of using 4M imidazole solution instead of solid 
imidazole for the buffering of incubation mixture was received in 2014 to further 
Patient plasma Buffered normal 
pool plasma
Factor VIII 
deficient 
plasma
Control mixture
1:1
Test mixture
1:1
Perform factor assay
Incubate at 37˚C for 2 hours
Calculate inhibitor units
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standardize the NA to increase test specificity (Verbruggen, personal 
communication). 
 
The frequently used cut-off value for both BA and NA is 0.6 BU/mL, however, 
owing to the increased specificity of the NA, the cut off value may be lower87. 
 
Despite all attempts to improve the sensitivity and specificity of the NA, low-titre 
inhibitors are still being missed (in particularly late ITI and early post ITI periods). A 
low-titre FVIII inhibitor assay (LTA) was developed in 2012 which was based on 
the principle of NA with the following changes: 
a) concentration of test plasma by selective protein filtration; 
b) the ratio for incubation mixture was 3:1 (concentrated test plasma: BNPP); 
c) residual FVIII activity was measured by the use of chromogenic substrates.  
The LTA offers the lower limit of detection of 0.03 BU/mL which cannot be 
detected by BA or NA, however clinical significance of these inhibitor <0.6 BU 
requires further studies87, 88. 
 
1.5 Rationale for the study 
In our centre, the currently used method for inhibitor measurement is the BA. 
Using this method, the estimated inhibitor frequency is 10-15% in the population 
attending the haemophilia treatment centre at the CMJAH. In view of the high 
treatment costs associated with management of inhibitors, it is important that the 
measurement is accurate and reliable. Using the BA, a large number of patients 
appear to have low levels of inhibitors with no clinical inhibitor effect. It is therefore 
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important to establish the clinical significance of these low level inhibitors using the 
more reliable NA. 
 
The following objectives were set in order to achieve the above aim: 
 To validate the NA against the BA in inhibitor measurement in a cohort of 
known inhibitor patients at the CMJAH Haemophilia Clinic; 
 To establish the clinically significant inhibitor cut-off value using the 
Nijmegen assay for our laboratory; 
 To retrospectively correlate borderline inhibitor levels obtained with BA and 
NA to the risk of development of low responding and high responding 
inhibitors. 
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2 MATERIALS AND METHODS 
2.1 Study design and site 
This study comprised of two parts:  
The laboratory validation of the NA was a cross-sectional study whilst the clinical 
correlation was done retrospectively. 
 
a) Laboratory: The method validation of the NA and establishing a clinically 
significant cut-off value as a cross-sectional study. This part of the study 
was conducted at the Department of Molecular Medicine and Haematology, 
National Health Laboratory Service, CMJAH. The validation of the NA also 
comprised of 2 parts where: 1) NA performed with buffered normal pooled 
plasma and 2) NA performed with buffered Dade® Citrol 1® Coagulation 
Control Level 1 (Siemens Healthcare Diagnostics, Newark, DE, USA).  
 
b) Clinical correlation: Retrospective data analysis was performed to 
determine the correlation between borderline inhibitor level and bleeding 
phenotype, as well as the risk of high responding inhibitor development. 
This part of the study was carried out at the Haemophilia Comprehensive 
Care Centre, Area 294, CMJAH.  
 
Permission to conduct this study, to use stored samples and to review patient’s 
files was given by the Chief Executive Officer of CMJAH and the Human Research 
Ethics Committee of the University of Witwatersrand, Johannesburg (see 
Appendix A for the permission letter and Appendix B for the ethics clearance 
certificate number M130539). 
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2.2 Study population 
a) Laboratory: 100 stored samples collected between January 2007 and 2013 
from patients previously tested with a positive inhibitor level, who attended 
HCCC, were utilized. The samples were collected during routine visits in 
diagnostic, treatment and/or monitoring follow-up of patients. Only the 
remaining samples after performing routine analyses were stored (refer to 
section 2.3 for samples handling). 
 
b) Clinical correlation:  Data from the patients of whom specimens were used 
in the validation study and known patients with high responding inhibitor, 
which were followed up at the CMJAH HCCC, were collected. Patients were 
of all ages and all visits in which inhibitor testing was performed were 
included.  
 
2.3. Blood samples handling 
2.3.1 Blood samples collection 
5 or 10mL of blood were routinely collected in BD Vacutainer® Citrate Tubes with 
3.2% buffered sodium citrate solution (BD Biosciences, San Jose, CA, USA) for 
inhibitor testing and/or monitoring as part of their full assessment while patients 
attended the clinic. The blood samples were taken by a trained haemophilia nurse 
or a haematology registrar using BD Vacutainer® Safety-Lok™ Blood Collection 
Sets with Luer Adaptors (BD Biosciences, San Jose, CA, USA) and BD 
Vacutainer® Holders (BD Biosciences, San Jose, CA, USA) to ensure that the 
samples were collected correctly. 
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2.3.2 Samples Preparation and Storage 
The samples were centrifuged in a Hettich® Rotofix 32A (Hettich, Tuttlingen 
Germany) centrifuge at 3500rpm (relative centrifugal force (RCF) of 1900 x g) for 
15 minutes in order to obtain platelet poor plasma (PPP). Plasma was removed 
and aliquoted into separate plastic tubes and/or Nunc CryoTube® Vials 
(ThermoFisher Scientific, Massachusetts, USA). Routine inhibitor tests were 
performed. The remaining plasma samples, from patients who previously tested 
positive for inhibitor, were then stored in cryovials at -70˚C until the validation 
study. 
 
2.4 The Classic Bethesda Assay 
The classic BA was performed according to the established method at the CMJAH 
using NHLS SOP: HAE0198. This entails the set of the following (see Figure 2.1):  
a) Standard: 400 mcL of NPP was added to 400 mcL of Owren-Koller (STA® 
Owren-Koller, Diagnostica Stago, Asnières sur Seine, France) which served 
as the calibrator and the standard control.  
b) Neat: 200 mcL of patient’s plasma was added to 200 mcL of NPP (1:1). 
c) Serial dilutions (see Figure 2.2) were set up by adding 200 mcL of Owren-
Koller in all the test tubes labelled 1:2 to 1:64 (in doubling quantity, more if 
required). A volume of 200 mcL of patient’s plasma was added to the 1:2 
tube, tap-mixed and 200 mcL of the mixture pipetted out and put into the 
next dilution tube (1:4). Similar principle applies to the subsequent doubling 
dilutions – 200 mcL Owren-Koller and 200 mcL of the previous mixture, tap-
mixed, move 200 mcL of the mixture to the next dilution tube. The extra 200 
mcL after mixing of the final tube of desired dilution was discarded. Finally,  
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200 mcL of NPP was pipetted into all the dilution tubes.  
 
All tubes were then mixed well, capped and incubated in a waterbath at 37˚C for 2 
hours. Factor FVIII assays were then performed on the post-incubated specimen 
using the “standard” tube as the calibrator. A residual FVIII activity of 25% - 75% 
was read off the Bethesda chart and multiplied with the dilution factor to obtain the 
inhibitor levels in Bethesda unit (BU/mL). 
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Figure 2.1. Flow diagram demonstrating the Bethesda Assay set up process. 
Abbreviations: NPP, Normal pooled plasma; BU/mL, Bethesda unit per millilitre. 
Standard (calibrator)
• 400 mcL of NPP was 
added to 400 mcL of 
Owren-Koller.
Neat
• 200 mcL of patient’s 
plasma was added to   
200 mcL of NPP (1:1)
Serial dilutions
•Set up by adding 200 mcL 
of Owren-Koller in all the 
test tubes labelled 1:2 to 
1:64 (in doubling quantity, 
more if required). 200 mcL 
of patient’s plasma was 
added to the 1:2 tube, tap-
mixed and 200 mcL of the 
mixture pipetted out and 
put into the next dilution 
tube
•Similar principle applies to 
the subsequent doubling 
dilutions – 200 mcL 
Owren-Koller and         
200 mcL of the previous 
mixture, tap-mixed, move 
200 mcL of the mixture to 
the next dilution tube.
•Discard the extra 200 mcL 
after mixing of the final 
tube of desired dilution
•200 mcL of NPP was 
pipetted into all the 
dilution tubes
Incubation
•All tubes were mixed well, 
capped and incubated in a 
waterbath at 37˚C for 2 
hours
Analysis
•Factor FVIII assays were 
then performed on the 
post-incubated specimen 
using the “standard” tube 
as the calibrator. 
•A residual FVIII activity of 
25% - 75% was read off 
the Bethesda chart and 
multiplied with the dilution 
factor to obtain the 
inhibitor levels in 
Bethesda unit (BU/mL)
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Figure 2.2. Flow chart demonstrating the setup of doubling dilutions. 
The flow chart shows how to setup doubling dilutions. Abbreviation: NPP, normal pooled plasma in BA or buffered normal pooled 
plasma in NA. Green, buffering agents (Owren-Koller in BA, FVIII deficient plasma in NA); blue, patient’s plasma. 
 Transfer 
200 mcL of 
mixture to the 
next dilution 
Transfer  
200 mcL of 
mixture to the 
next dilution 
Transfer  
200 mcL of 
mixture to the 
next dilution 
 
… etc. 
(subsequent 
dilutions) 
 
 Discard 
the extra  
200 mcL of 
mixture 
1:2 1:4 1:8 
Final desired 
dilution 
 Add  
200 mcL of 
NPP into each 
of the dilution 
tubes 
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2.5 Establishment of the Nijmegen Modification of the Bethesda Assay  
2.5.1 pH measurement 
All pH analyses of imidazole solution and plasma were performed on the 
pH/conductivity meter C561 (Consort, Turnhout, Belgium) in the cytogenetics 
branch of haematology laboratory at NHLS, CMJAH. The QC and maintenance for 
the pH meter were done according to NHLS SOPs namely NJHC0232 and 
FML0408. 
 
2.5.2 Preparation of Imidazole buffer 
All solid imidazole (Sigma-Aldrich, ≥99% (titration), crystalline, MW = 68.08, St. 
Louis, Missouri, USA) mass determinations were performed on the AE ADAM 
PGW Precision Balance (AE ADAM, Kingston, MK, UK) and Sartorius CPA 3245 
(Sartorius, Göttingen, Germany) weight balance scales in the flow bench and the 
main laboratory respectively. The QC and maintenance of the scales were done 
according to NHLS SOPs namely GPL0062, FML0738, GPL2335 and NJHH0202. 
 
2.5.3 FVIII inhibitor testing 
All FVIII inhibitor analyses were performed on the STA-R Evolution® Expert Series 
(Diagnostica Stago, Asnières sur Seine, France) instrument in the coagulation 
bench of the haematology laboratory at the NHLS, CMJAH. The QC and 
maintenance of the instruments were performed according to the NHLS SOPs: 
GPL2472. 
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2.5.4 Reagents storage and preparation 
The storage and preparation of the reagents were carried out according to the 
corresponding package inserts and NHLS SOP GPL2849. 
 Partial thromboplastin time reagent (PTT Automate 5, Diagnostica Stago, 
Asnières sur Seine, France), FVIII deficient plasma (STA® Deficient FVIII, 
Diagnostica Stago, Asnières sur Seine, France), Owren-Koller buffer and 
CaCl2 (STA- CaCl2 0.025M, Diagnostica Stago, Asnières sur Seine, France) 
were stored at 2-8˚C and were expected to remain stable until the 
expiration date on the box label. 
 Partial thromboplastin time reagent was reconstituted with 5mL of distilled 
water with a 30-minute stabilization time at room temperature (18 - 25˚C) 
and mixed rigorously by turning the vial upside down 5-10 times to obtain a 
homogeneous solution before loading onto the analyser. On board stability 
was for 24 hours with the original perforated cap and the reconstituted 
reagent remained stable for 7 days at 2-8˚C in the original capped vial. 
 The STA® Deficient FVIII contains lyophilized citrated human plasma from 
which FVIII has been removed by selective Immuno-adsorption. The factor 
VIII deficient plasma was reconstituted with 1mL of distilled water with a 30-
minute stabilization time at room temperature and then the vial was swirled 
gently to obtain a homogeneous solution before loading onto the analyser. 
On board stability is 4 hours. The FVIII deficient plasma was verified as part 
of the validation of the Stago analyser. This is confirmed by using a positive 
and negative commercial control prior to undertaking a FVIII assay as part 
of routine laboratory quality control. 
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 Owren-Koller buffer and CaCl2 were ready for use (no stabilization time 
needed) with an on board stability of 72 hours without cap. 
 
2.5.5 The Normal Pooled Plasma 
The Normal Pooled Plasma was purchased from the South African National Blood 
Service (SANBS) (SANBS, Roodepoort, Johannesburg, South Africa) as “frozen 
Negative Plasma pooled” (PRU014, SANBS, RSA). Upon receiving the frozen 
pooled plasma, the unit was thawed in a 37˚C water bath. One millilitre aliquots 
were immediately prepared in cryo tubes and stored at -70˚C until used. The NPP 
was tested for PT and PTT to ensure its normality and serve as a baseline for 
subsequent monitoring. 
 
2.5.6 Preparing a 4M imidazole solution at a pH of 7.4 
The 4M imidazole solution at pH of 7.4 was prepared by adding crystalline 
imidazole into sterile water (Sabex, Boucherville, QC, Canada) then buffered with 
10N HCl by titration to a pH of 7.4 (without changing the concentration/total 
volume of the desired mixture). The 4M imidazole solution was then stored in a 
closed plastic container in a 2-8˚C fridge for up to two months and used as 
required. 
 
2.5.7 Preparation of Buffered Normal Pooled Plasma / Citrol 1 
2.5.7.1 Direct buffering of NPP/Citrol 1 with solid Imidazole 
The NPP/Citrol 1 was buffered by adding crystalline imidazole (Sigma-Aldrich, St. 
Louis, MO, USA) to obtain a concentration of 0.1M. The mixture was then titrated 
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to a pH of 7.4 by adding 1N HCl slowly. The BNPP and BC were then aliquoted 
into Cryo tubes and stored at -70˚C until use. 
 
2.5.7.2 Buffering of NPP/Citrol 1 using 4M Imidazole solution  
The NPP/Citrol 1 was freshly buffered by adding the pre-prepared 4M imidazole 
solution at the ratio of 3.9mL NPP/Citrol1 to 0.1mL 4M imidazole solution in a 
plastic container. The mixture was then buffered with 10N HCl by titration to a pH 
of 7.4.  
 
2.5.8 The Nijmegen Modification of the Bethesda Assay 
The NA was performed by modifying the original BA SOP HAE0198.  
 
Set-up (refer to Figure 2.3) 
400 mcL of NPP and 400 mcL of FVIII deficient plasma was pipetted to the first 
plastic tube (labelled “STD”) which served as the calibrator and the standard 
control. 200 mcL of patient’s plasma and 200 mcL of BNPP/BC was pipetted into 
the second plastic tube to act as the “neat” (1:1). Doubling dilutions (ranging from 
1:1 to 1:64, more if required) was set up by pipetting 200 mcL of FVIII deficient 
plasma along with 200 mcL of patient plasma into a third plastic tube labelled 1:2. 
Next, 200 mcL of FVIII deficient plasma was added to 200 mcL of 1:2 dilution into 
a fourth plastic tube labelled 1:4 and thereof. The extra 200 mcL after mixing of the 
final tube of desired dilution was discarded. Finally, 200 mcL of BNPP/BC was 
pipetted into each of the series of dilution tubes (see Table 2.1 and Figure 2.2). 
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All tubes were then mixed well, capped and incubated in the waterbath at 37˚C for 
2 hours.  
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Figure 2.3. Flow diagram demonstrating the Nijmegen set up process 
Abbreviations: NPP, Normal pooled plasma; Citrol 1, Dade® Citrol 1® Coagulation Control Level 1; HCl, Hydrochloric acid; M, mole 
per litre; N, normal.  
Buffering
• Direct buffering
• NPP/Citrol 1 was 
buffered by adding 
crystalline imidazole to 
obtain a concentration 
of 0,1M. 
• The mixture was then 
adjusted to a pH of 7.4 
by adding 1N HCl 
slowly
• Buffering with 4M 
imidazole solution
• preparation: add 
crystalline imidazole 
into sterile water and 
then buffered with 10N 
HCl until a pH of 7.4 
• NPP/Citrol 1 was 
freshly buffered by 
adding the pre-
prepared 4M imidazole 
solution at the ratio of 
3,9mL NPP/Citrol1 to 
0,1mL 4M imidazole 
solution. 
• The mixture was then 
buffered with 10N HCl 
until pH of 7.4 was 
obtained
Standard 
(calibrator)
• 400 mcL of NPP was 
added to 400 mcL of 
FVIII deficient plasma.
Neat
• 200 mcL of patient’s 
plasma was added to 
200 mcL of buffered 
NPP/Citrol 1 (1:1)
Serial dilutions
• Set up by adding       
200 mcL of FVIII 
deficient plasma in all 
the test tubes labelled 
1:2 to 1:64 (in doubling 
quantity, more if 
required). 200 mcL of 
patient’s plasma was 
added to the 1:2 tube, 
tap-mixed and 200 mcL 
of the mixture pipetted 
out and put into the next 
dilution tube
• Similar principle applies 
to the subsequent 
doubling dilutions –
200 mcL of FVIII 
deficient plasma and 
200 mcL of the previous 
mixture, tap-mixed, 
move 200 mcL of the 
mixture to the next 
dilution tube.
• Discard the extra       
200 mcL after mixing of 
the final tube of desired 
dilution
• 200 mcL of NPP was 
pipetted into all the 
dilution tubes
Incubation
• All tubes were mixed 
well, capped and 
incubated in a waterbath 
at 37˚C for 2 hours
Analysis
• Factor FVIII assays 
were then performed on 
the post-incubated 
specimen using the 
“standard” tube as the 
calibrator. 
• A residual FVIII activity 
of 25% - 75% was read 
off the Bethesda chart 
and multiplied with the 
dilution factor to obtain 
the inhibitor levels in 
Bethesda unit (BU/mL)
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Table 2.1. Scheme of Nijmegen Assay sample preparation. 
Tube STD Neat (1:1) 1:2 1:4 1:8 1:16 1:32 1:64 etc.. 
F8 def 
(mcL) 
200 X 200 200 200 200 200 200  
Patient 
plasma 
(mcL) 
X 200 200 200 (1:2) 200 (1:4) 200 (1:8) 200 (1:16) 200 (1:32)  
Mix & 
transfer 
(mcL) 
X X 200 200 200 200 200 200 etc.… then 
mix & 
discard 200 
mcL from 
last tube 
BNPP/BC 
(mcL) 
200 200 200 200 200 200 200 200  
Abbreviations: STD, standard control (calibrator); def, deficient; BNPP, buffered normal pool plasma; BC, buffered Dade® Citrol 
1® Coagulation Control Level 1; X, add nothing in the tube; mcL, microlitre; etc., subsequent dilution tubes. 
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Post incubation 
The STA-R Evolution® Expert Series was calibrated with the tube labelled “STD” 
with “FVIII INH" setting (assuming factor assay value of the standard control is 
100%). After calibration is completed and passed, QC was performed by running a 
FVIII INH (essentially the same as factor assay which is a one-stage clot-based 
assay) on the same standard control to ensure the calibration of the analyser was 
correct and the result should be between 90-110%.  Once QC passed, FVIII INH 
was then performed on the remaining incubated samples. The dilution of the 
samples that gave the residual factor within the range of 25%-75% were read off 
the Bethesda chart (see Table 2.2) and then multiplied by the dilution factor in 
order to obtain the inhibitor level in Nijmegen-Bethesda units (NBU). 
 
  
41 
 
Table 2.2. Bethesda Chart. 
This chart is derived from the Bethesda graph which was based on the definition of 
the test plasma contains 1 BU/mL at 50% inhibition89.  
RESIDUAL 
FACTOR (%) 
BETHESDA 
UNIT (BU/ML) 
RESIDUAL 
FACTOR (%) 
BETHESDA 
UNIT (BU/ML) 
75 0.42 49 1.03 
74 0.451 48 1.05 
73 0.47 47 1.08 
72 0.49 46 1.12 
71 0.51 45 1.15 
70 0.54 44 1.18 
69 0.55 43 1.23 
68 0.56 42 1.25 
67 0.59 41 1.28 
66 0.60 40 1.33 
65 0.62 39 1.36 
64 0.65 38 1.40 
63 0.66 37 1.44 
62 0.70 36 1.47 
61 0.72 35 1.52 
60 0.74 34 1.55 
59 0.75 33 1.60 
58 0.80 32 1.64 
57 0.82 31 1.69 
56 0.83 30 1.71 
55 0.85 29 1.77 
54 0.89 28 1.82 
53 0.91 27 1.87 
52 0.95 26 1.93 
51 0.98 25 2.00 
50 1.00   
Abbreviation: BU/mL, Bethesda unit per millilitre. 
 
2.5.9 Control samples 
For precision, accuracy and linearity analyses, commercial samples (with assigned 
inhibitor values) were used (see Table 2.3). These samples were prepared and 
validated by the External quality Control of diagnostic Assays and Tests (ECAT) 
Foundation (Dobbeweg 1, 2254 AG Voorschoten, The Netherlands) External 
Quality Assessment Programme (EQAP). 
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Table 2.3. ECAT control samples and expected values with 2SD 
ECAT reference 
samples 
Expected value ECAT mean ±2SD 
INH-24 0.5 0.0 - 1.2 
INH-25 2.8 1.0 - 4.6 
INH-26 6.1 2.1 - 10.1 
Abbreviations: ECAT, ECAT foundation; SD, standard deviation; INH-24, -25, -26, 
ECAT control samples. 
 
2.5.10 Precision Analysis 
Precision is defined as the closeness of agreement (degree of scatter) between a 
series of measurements obtained from multiple sampling of the same 
homogeneous sample under the prescribed conditions90.  
 
The precision analyses were assessed by performing the NA using BNPP/BC 
eleven times within a single run. One value was excluded per analysis and the 
standard deviation (SD), coefficient of variation (CV) and confidence interval (CI) 
were then calculated. 
 
2.5.11 Accuracy Analysis 
The accuracy of an analytical procedure expresses the closeness of agreement 
between the value which is accepted either as a conventional true value or an 
accepted reference value and the value found90. 
 
The accuracy analysis for NA was assessed by: 
a) the results from the NA of three control samples with different 
concentrations were compared with the accepted reference values provided 
by the ECAT foundation; 
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b) the results from the NA using BNPP of 100 patient samples and NA using 
BC of 43 patient samples with a range of different concentrations (negative 
to high) were compared to the results obtained from the BA. 
 
The difference between the NA measured value and the accepted true value (BA) 
together with the % bias, 95% confidence intervals were then calculated and 
represented in the Bland-Altman plot. Correlation studies between NA measured 
value and accepted true value with R2, Y-intercept and slope were calculated and 
represented by linear regression analysis. 
 
2.5.12 Linearity Analysis  
The linearity of an analytical procedure is its ability (within a given range) to obtain 
test results which are directly proportional to the concentration (amount) of analyte 
in the sample 90. 
 
The linearity analyses were performed by constituting nine diluted samples 
covering the interested range (≤5BU) from a control sample (with a known 
concentration) using FVIII deficient plasma as diluent. The results obtained from 
NA were then compared against the expected concentrations of the diluted 
samples. The results were then plotted with correlation coefficient, y-intercept, 
slope of the regression line and residual sum of square calculated. 
 
2.5.13 Clinical data collection 
A clinical correlation study was carried out concurrently with the method validation. 
The clinical data collection included a retrospective review of clinical files, 
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laboratory results and clinical trial data of the patients correlating with the available 
samples as well as known patients with inhibitors. Patients with von Willebrand 
disease, haemophilia B, acquired haemophilia or those who did not have a 
corresponding sample were excluded in the final analyses. 
 
Parameters including demographics (age, gender, race), severity of the 
haemophilia, HIV status, presence of “transient” inhibitor, type of treatment (on 
demand or prophylaxis), type of replacement product, dosage given and exposure 
days were collected and compared to inhibitor development. The inhibitor levels 
were compared to bleeding frequency and response to the bypassing agents of 
the patients.  
 
In a subset of patients (known inhibitor patients), the association between the 
presence of “transient” inhibitor and the development of high responding inhibitor 
were analyzed by going through the available patients’ records and response to 
treatment documented in the patients’ files. 
 
2.5.14 Establishing the clinical significant cut-off value 
The NA measured inhibitor values were correlated with the clinical presentation. 
The data was plotted in a 2 x 2 contingency table and true positive rate (TPR), 
false positive rate (FPR), positive predictive value (PPV), F1 score and accuracy 
(ACC) were calculated. The clinically significant cut-off value was determined by 
plotting the data into a Receiver Operating Characteristic (ROC) curve and the 
area under the curves (AUC) values were calculated. 
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2.5.15 Statistical Analysis 
Accuracy analyses (linear regression and Bland-Altman plot) and linearity 
analyses (linear regression) were performed using GraphPad Prism® version 6 for 
Mac (GraphPad Software, San Diego, CA). Precision analyses (SD, %CV and 
95% CI)  and clinical data analyses were performed with Numbers version 3.2 
(Apple Inc, Cupertino, CA, USA).  
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3 RESULTS 
3.1. Laboratory validation: 
The NA method validation was performed using both normal pooled plasma as 
well as Citrol 1 (which is commercially available and more standardized) with the 
possibility of replacing NPP with Citrol 1.  
 
3.1.1 NA (Direct buffering of NPP with solid Imidazole) 
3.1.1.1 Precision analysis 
The results of precision analysis using BNPP are shown in Table 3.1. 
Table 3.1. Precision analysis of NA using BNPP 
Sample A NA-BNPP 
1 0.72 
2 0.65 
3 0.66 
4 0.66 
5 0.72 
6 0.54 
7 0.70 
8 0.74 
9 0.74 
10 0.62 
Abbreviations: sample A, random biological sample; NA, Nijmegen Assay; BNPP, 
buffered normal pooled plasma. 
 
Precision analysis of NA using BNPP showed a SD of 0.06, %CV of 9.3% and a 
95% CI of 0.68 ± 0.04. 
 
3.1.1.2 Accuracy analysis  
The result of accuracy analysis using BNPP with ECAT control samples are shown 
in Table 3.2. 
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Table 3.2. Accuracy analysis of NA using BNPP (control samples) 
ECAT  
Reference 
sample 
ECAT values 
(BU/mL) 
BA 
(BU/mL) 
NA with BNPP 
(NBU/mL) 
INH-24-reference 0.5 1.05 1.03 
INH-25-reference 2.8 3.86 5.44 
INH-26-reference 6.1 7.48 7.48 
Abbreviations: ECAT, ECAT foundation; INH-24, -25, -26, ECAT inhibitor control 
samples; BA, Bethesda Assay; NA, Nijmegen Assay; BNPP, buffered normal 
pooled plasma; BU/mL, Bethesda unit per millilitre; NBU/mL, Nijmegen-Bethesda 
unit per millilitre. 
 
3.1.2 NA (Direct buffering of Citrol 1 with solid Imidazole)  
3.1.2.1 Precision analysis  
The results of precision analysis using BC are shown in Table 3.3. 
Table 3.3. Precision analysis of NA using BC 
SAMPLE A NA-BC 
(NBU/mL) 
1 0.75 
2 0.74 
3 0.98 
4 0.83 
5 0.72 
6 0.65 
7 0.70 
8 0.85 
9 0.89 
10 0.83 
Abbreviations: sample A, random biological sample; NA, Nijmegen Assay; BC, 
buffered Dade® Citrol 1® Coagulation Control Level 1; NBU/mL, Nijmegen-
Bethesda unit per millilitre. 
 
Precision analysis of NA using BC showed a SD of 0.1, %CV of 12.56 and 95% CI 
of 0.79 ± 0.02. 
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3.1.2.2 Accuracy analysis  
The results of accuracy analysis using BC with the ECAT control samples are 
shown in Table 3.4. 
Table 3.4. Analysis of NA using BC (control samples) 
ECAT reference 
samples 
ECAT values 
(BU/mL) 
BA  
(BU/mL) 
NA with BC 
(NBU/mL) 
INH-24-reference 0.5 1.05 1.28 
INH-25-reference 2.8 3.86 7.08 
INH-26-reference 6.1 7.48 14.16 
Abbreviations: ECAT, ECAT foundation; INH-24, -25, -26, ECAT inhibitor control 
samples; BA, Bethesda Assay; NA, Nijmegen Assay; BC, buffered Dade® Citrol 
1® Coagulation Control Level 1; BU/mL, Bethesda unit per millilitre; NBU/mL, 
Nijmegen-Bethesda unit per millilitre. 
 
 
3.1.3 NA (Buffering of NPP using 4M Imidazole solution) 
3.1.3.1 Precision analysis 
The results of precision analysis using BNPP are shown in Table 3.5.  
Table 3.5. Precision analysis of NA using BNPP 
INH-24 NA-BNPP 
(NBU/mL) 
1 0.72 
2 0.85 
3 0.75 
4 0.66 
5 0.80 
6 0.80 
7 0.85 
8 0.82 
9 0.70 
10 0.74 
Abbreviations: INH-24, ECAT control sample; NA, Nijmegen Assay; BNPP, 
buffered normal pooled plasma; NBU/mL, Nijmegen-Bethesda unit per millilitre. 
 
Precision analysis of NA using BNPP showed a SD of 0.06, %CV of 8.44 and 95% 
CI of 0.77 ± 0.05. 
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3.1.3.2 Accuracy analysis  
The results of accuracy analysis using BNPP with control sample are shown in 
Table 3.6. 
Table 3.6. Analysis of NA using BNPP (control sample) 
ECAT  
reference sample 
ECAT values 
(BU/mL) 
BA 
(BU/mL) 
NA with BNPP 
(NBU/mL) 
INH-24-reference 0.5 0.95 0.65 
INH-25-reference 2.8 3.86 3.64 
INH-26-reference 6.1 12.16 8.24 
Abbreviations: ECAT, ECAT foundation expected value; INH-24, -25, -26, ECAT 
inhibitor control samples; BA, Bethesda Assay; NA, Nijmegen Assay; BNPP, 
buffered normal pooled plasma; BU/mL, Bethesda unit per millilitre; NBU/mL, 
Nijmegen-Bethesda unit per millilitre. 
 
All three control samples showed measured values within ECAT assigned values. 
 
One hundred patient samples were analysed using BNPP buffered with 4M 
imidazole solution. The results are shown in Figure 3.1 and Figure 3.2. 
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Figure 3.1. Linear regression graph demonstrating NA using BNPP against 
BA. 
Abbreviations: BA, Bethesda Assay; NA, Nijmegen Assay; BU/mL, Bethesda unit 
per millilitre; NBU/mL, Nijmegen-Bethesda unit per millilitre; BNPP, buffered 
normal pooled plasma. Blue line represents linear regression between BA and NA 
with BNPP and the red dotted line represent the 95% confidence interval. 
 
Correlation studies between NA (BNPP) and BA showed a R2 = 0.93 (P-value 
<0.0001), Y-intercept = -0.89 and slope of 1.06 ± 0.03. 
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Figure 3.2. Bland-Altman plot demonstrating accuracy between BA and NA 
with BNPP.  
Abbreviations: BA, Bethesda Assay; NA, Nijmegen Assay; BNPP, buffered normal 
pooled plasma. Blue dotted line represents the bias and red dotted lines represent 
95% confident interval. 
 
Comparative study using the Bland-Altman plot showed a bias = 0.49, SD of bias 
= 4.4 and 95% limits of agreement from -8.13 to 9.11. 
 
In addition, the NA with BNPP provides a sensitivity of 100%, specificity of 94.5%, 
false positive rate of 5.5% and false negative rate of 0%. 
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3.1.3.3 Linearity analysis 
The results of linearity analysis using BNPP are shown in Figure 3.3. 
 
Figure 3.3. Linearity analysis of NA with BNPP. 
Abbreviations: NA, Nijmegen Assay, BNPP, buffered normal pooled plasma, 
BU/mL, Bethesda unit per millilitre; NBU/mL, Nijmegen-Bethesda unit per millilitre.  
 
 
Linearity analysis of NA (BNPP) in lower ranges (0.2 - 5 BU/mL) shows R2 = 0.98 
(P-value <0.0001), Y-intercept = 0.01 and slope = 1.05 ± 0.05. 
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3.1.4 NA (Buffering of Citrol 1 using 4M Imidazole solution) 
3.1.4.1 Precision analysis 
The results of precision analysis using BC are shown in Table 3.7. 
Table 3.7. Precision analysis of NA using BC 
ECAT INH 24 NA-BC 
(NBU/mL) 
1 1.03 
2 1.05 
3 1.03 
4 1.00 
5 0.83 
6 0.83 
7 0.85 
8 0.83 
9 0.95 
10 0.89 
Abbreviations: INH-24, ECAT control sample; NA, Nijmegen Assay; BNPP, 
buffered normal pooled plasma; NBU/mL, Nijmegen-Bethesda unit per millilitre; 
max, maximum; min, minimal. 
 
Precision analysis of NA with BC shows SD of 0.09, %CV of 10 and 95% CI of 
0.93 ± 0.02. 
 
3.1.4.2 Accuracy analysis  
The results of accuracy analysis using BC with ECAT control samples are shown 
in Table 3.8.  
Table 3.8. Analysis of NA using BC (control sample) 
ECAT reference 
samples 
ECAT values 
(BU/mL) 
BA 
(BU/mL) 
NA with BC 
(NBU/mL) 
INH-24-reference 0.5 0.95 1.03 
INH-25-reference 2.8 3.86 4 
INH-26-reference 6.1 12.16 10.24 
Abbreviations: ECAT, ECAT foundation expected value; INH-24, -25, -26, ECAT 
inhibitor control samples; BA, Bethesda Assay; NA, Nijmegen Assay; BC, buffered 
Dade® Citrol 1® Coagulation Control Level 1; BU/mL, Bethesda unit per millilitre; 
NBU/mL, Nijmegen-Bethesda unit per millilitre. 
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In the 2 ECAT samples with mean <5BU (INH-24 and INH-25) showed measured 
results within the ECAT assigned values, however, INH-26 showed a 
measurement outside of the assigned value. 
 
Forty-three patient samples were analysed using Citrol 1 buffered with 4M 
imidazole solution. The results are shown in Figure 3.4 and Figure 3.5. 
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Figure 3.4. Linear regression graph demonstrating NA using BC against BA. 
Abbreviations: BA, Bethesda Assay; NA, Nijmegen Assay; BU/mL, Bethesda unit 
per millilitre; NBU/mL, Nijmegen-Bethesda unit per millilitre; BC, buffered Dade® 
Citrol 1® Coagulation Control Level 1. Blue line represents linear regression 
between BA and NA with BC and the red dotted line represent the 95% confidence 
interval. 
 
Correlation studies between NA (BC) and BA shows R2 = 0.76 (P-value <0.0001), 
Y-intercept = 0.86 and slope of 0.54 ± 0.05. 
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Figure 3.5. Bland-Altman plot demonstrating accuracy between BA and NA 
with BC. 
Abbreviations: BA, Bethesda Assay; NA, Nijmegen Assay; BC, buffered Dade® 
Citrol 1® Coagulation Control Level 1. Blue dotted line represents the bias and red 
dotted lines represent 95% confident interval. 
 
Comparative study using the Bland-Altman plot shows a bias = 0.81, SD of bias = 
3.9 and 95% limits of agreement from -6.84 to 8.46. 
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3.1.3.3 Linearity analysis 
 
 
Figure 3.6. Linearity analysis of NA with BC. 
Abbreviations: NA, Nijmegen Assay, BC, buffered Dade® Citrol 1® Coagulation 
Control Level 1; BU/mL, Bethesda unit per millilitre; NBU/mL, Nijmegen-Bethesda 
unit per millilitre. 
 
Linearity analysis of NA (BC) in lower ranges (0.2 - 5 BU/mL) shows R2 = 0.97 (P-
value <0.0001), Y-intercept = 0.11 and slope = 1.18 ± 0.08. 
 
 
3.2. Clinical correlation studies 
In the clinical correlation studies, a total of 82 patient files were reviewed. Of 
which, 10 patients did not have corresponding samples and were therefore 
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excluded. In addition, patients with acquired haemophilia, haemophilia B and von 
Willebrand disease are also excluded (see Figure 3.7). 
 
 
Figure 3.7. Flow diagram indicating the number of patient files reviewed, 
exclusion criteria and total number analyzed. 
 
  
n = 82
patient files reviewed
n = 64
further analysis
Total exclusion (n = 18)
- does not have samples (n = 10)
- acquired haemophilia (n = 3)
- von Willebrand disease (n = 4)
- haemophilia B (n = 1)
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Table 3.9. Characteristics of patients analyzed. 
Parameters Number Percentage (%) 
Gender:     
 Male 63 98,44 
 Female 1 1,56 
Ethnicity:     
 African 37 57,81 
 White 24 37,50 
 Coloured 2 3,13 
 Indian 1 1,56 
Severity:    
 Moderate 9 14,06 
 Severe 55 85,94 
Age group:     
 Paeds (less than 16) 21 32,81 
 Adults 43 67,19 
HIV status:     
 HIV + 4 6,25 
 HIV - 60 93,75 
Known with inhibitor treated 
with a bypassing agent: 
    
 Yes 20 31,25 
 No 44 68.75 
Treatment strategy:     
 Prophylaxis 6 9,38 
 On demand 58 90,63 
   
 
The 6 patients described in Table 3.9 who received prophylactic therapy were all 
paediatric patients. In addition, patients treated with bypassing agents were all 
receiving on-demand treatment. 
 
Of the analyzed patients, patients with high titre-inhibitors treated with bypassing 
agents comprised of approximately one third. Only 3 of the 20 high-titre inhibitor 
patients had a clear history of presence of transient inhibitor prior to the 
development of clinically significant inhibitor. The remaining 17 high-titre inhibitor 
patients have incomplete data regarding the presence of transient inhibitor as 
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most of these patients are adult and they were diagnosed before routine inhibitor 
testing/monitoring was implemented. All 44 patients with previously recorded low-
titre, most likely “transient” inhibitor have achieved haemostasis with normal dose 
CFC and did not required increased dosage of CFC nor bypassing agents to date. 
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4 DISCUSSION 
Although haemophilia is a rare disorder, the management of and expertise 
required to manage these patients is a costly undertaking. The development of 
inhibitors (in particularly high titre) is one of the most serious complications of CFC 
treatment rendering standard replacement therapy useless. These inhibitors have 
unpredictable kinetics as well as variable patient responses to different bypassing 
agents making the management of these patients challenging.  
 
Historically, the gold standard of inhibitor determination is by the Bethesda assay 
which was developed in the 1970’s. The nature (high sensitivity but lack of 
specificity) of Bethesda assay is deemed problematic particularly when it comes to 
low-titre inhibitors. In addition, with routine monitoring of inhibitors becoming more 
common, the phenomenon of transient inhibitors was discovered. In the 90’s, the 
Nijmegen modification of the Bethesda Assay was introduced and was proven to 
be more reliable than BA in low-titre ranges.  
 
Aim of the study 
Multiple studies82, 83, 91 have already been conducted and concluded that NA 
provides more reliable results in low titre ranges. However, LTA was in 
development recently88 and was suggested that it may be superior for post ITI 
monitoring. Nevertheless, the primary objective of this study was to validate the 
NA against BA in a cohort of patients with inhibitors (regardless of titre) as well as 
determining a clinically significant cut-off value for our laboratory. Another 
objective of this study was to determine the significance of the low-titre (possibly 
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transient) inhibitors (i.e. whether they eventually become clinically significant 
requiring treatment with a bypassing agent). 
 
4.1 Validation of NA using different buffered reagents 
4.1.1 NA (Direct buffering with solid Imidazole) 
Most studies conducted previously were utilizing NPP as buffered reagent. In this 
study, the NA has been validated with both buffered NPP and Citrol 1 against BA. 
The NA was initially set up according to the publication by Verbruggen82 using 
direct buffering of fresh frozen pooled plasma/Citrol 1 with solid imidazole to a 
0.1M concentration. The NPP/Citrol 1 was then adjusted to a pH of 7.4 with 1N 
HCl.  
 
Precision analyses for both direct buffering with NPP or Citrol 1 were similar but 
NA (using BC) appeared to give us a higher mean, higher SD as well as higher 
%CV. When ECAT control samples (INH-24, -25 and -26) were analysed using 
NPP and Citrol 1 that were directly buffered, one level for NPP and all three for 
Citrol 1 were outside of the assigned values. This could possibly be explained by 
the variation or inaccuracy of measurement of imidazole powder and the dilutional 
effect with the use of 1N HCl during buffering (the volume required to achieve pH 
of 7.4 with 1N HCl was quite significant).  
 
4.1.2 NA (using 4M Imidazole solution) 
The use of 4M imidazole solution and a higher concentration of HCl (10N) to 
obtain pH of 7.4 seems to have eliminated the discrepancies in measurement. The 
precision analyses of NA buffered with 4M imidazole solution using NPP or Citrol 1 
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showed a better %CV when compared to the respective original (direct buffering) 
NA with NPP or Citrol 1.  
 
Using the same ECAT control samples, NA with NPP obtained measured values 
within the assigned values using all three levels. Meanwhile, NA with Citrol 1 
improved and only the high-titre level did not achieve a measured value within the 
assigned value. NA correlated well and was comparable with BA but the slope 
obtained with NPP was superior to Citrol 1. NA with NPP gave a smaller bias than 
Citrol 1, however both were within acceptable limits.  
 
Linearity studies was only performed at the range of interest (i.e. low-titre inhibitor 
range of 0-5 BU/mL) revealing both NA with NPP and Citrol 1 were linear but NPP 
had a better slope being closer to the expected measurements than Citrol 1.  
 
In general, NA with Citrol 1 appeared to give higher measurements than BA and 
NA with NPP. Another major difficulty experienced throughout this project was the 
QC and calibrating processes when using Citrol 1 in comparison to NPP. This 
could be explained by the fact that Citrol 1 is a lyophilized preparation. The FVIII in 
lyophilized preparations is less stable as compared to FVIII in fresh or frozen 
plasma (according to the package insert, the Citrol 1 is stable for 8 hours after 
reconstitution in closed vial at room temperature. Owing to the need for buffering 
as well as incubation, reconstituted Citrol 1 could not be kept in the original vial 
which could have contributed to FVIII instability. Moreover, FVIII can be inactivated 
during the buffering process resulting in an even lower FVIII level than NPP. For 
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the above reasons, the Citrol 1 arm of the study was terminated early due to 
technical difficulties and limited funding for reagents.  
 
There is no other intra- or inter-laboratory data available in South Africa as this is 
the first NA set-up and validation performed. 
 
4.1.3 Other observations 
Of interest, 23 of 34 samples previously measured with lower-titre inhibitor when 
the sample was first submitted no longer have a measurable inhibitor. The 
significance of this discrepancy in measurement over time is uncertain. The 
remaining 11 samples with previously measured values, 9 of 11 samples were 
from known inhibitor patients treated with a bypassing agent demonstrating 
clinically significant low-titre inhibitors did not alter over time. Only 1 of 100 
samples that showed no inhibitor on BA demonstrated a low-titre inhibitor on NA 
with NPP, but a measured value of 0.49 NBU/mL was nonetheless deemed 
negative when using the international cut off value of 0.6 NBU/mL. 
 
In this study, the NA with NPP was comparable to BA and showed acceptable 
precision, accuracy and linearity but could not be demonstrated to be superior to 
the current BA.   
 
4.2 Clinical correlation and low-titre transient inhibitors 
Only 15% of the known inhibitor patients had transient inhibitors prior to the 
development of clinically significant inhibitors and required a change of treatment 
from CFC to bypassing agents.  
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The investigators could not conclusively demonstrate the presence of the transient 
inhibitor eventually becoming clinically significant. This phenomenon concurred 
with the suggestion of previous studies that the transient inhibitors represented the 
natural tolerance to the CFC given. 
 
4.3 Limitation of the study 
The samples were stored over several years and the acquired NPP was stored in  
-80˚C for over 1 month; the investigators could not determine how much, if any, 
sample degradation has occurred which may have partly affected the results. 
Owing to the limited amount of reagents, the Citrol 1 arm of the study was 
terminated early limiting the sample size to be less than the NPP arm. In addition, 
the accuracy analyses were not performed in duplicate. 
 
Both the lack of previous transient inhibitor studies and the lack of available data in 
known high-titre inhibitor patients (before the diagnosis was made) hinder the 
interpretation of the significance of transient inhibitors.  
 
ROC curves for NA with NPP and Citrol 1 could not be established owing to the 
limited sample size.  
 
4.4 Recommendation 
The NA with Citrol 1 showed inferior results compared to NA with NPP. In addition, 
owing to the technical difficulties experienced, NA with Citrol 1 is not 
recommended for routine inhibitor testing. The NA performed with NPP buffered 
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with 4M imidazole solution could be implemented in our laboratory and could 
replace the current BA.  
 
The international agreed cut of value of 0.6 NBU/mL should be used. 
 
Only NPP and Citrol 1 were considered as buffered reagents when we designed 
the study, other buffered reagents (such as National Bioproducts Institute 
Bioplasma FDP or STA-Pool Norm) should be investigated as alternative to NPP.  
 
Prospective long-term studies are needed to determine the nature and significance 
of the transient inhibitor.  
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5 Conclusion 
In this validation assay using patient and control samples, the NA performed better 
when using 4M imidazole solution for both NPP and Citrol 1 when compared to NA 
using solid imidazole direct buffering. The performance of the Nijmegen assay with 
buffered pool plasma was better than that of the same assay using buffered Citrol 
1.  
 
The performance of the NA with BNPP is comparable to the currently used BA. 
However, the investigators cannot demonstrate the NA to be superior in this study. 
 
While not conclusive, the results of this study suggests that the presence of 
transient low-titre inhibitor does not predict the development of future clinically 
significant inhibitors.  
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